About

Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.

Articles

Drug-coated Balloons short

Published:

01 September 2018

Citation:

Vascular & Endovascular Review 2018;1(1):8–11.

A Multicentre, Open-Label, Randomised Controlled Clinical Trial to Assess the Efficacy and Safety of Appropriate Target Values for Lipid Management in Patients who Have Mild to Moderate Stenotic Lesions with High-Risk Plaques in Coronary Arteries: Study P

Published:

15 May 2020

Citation:

European Cardiology Review 2020;15:e47.

Atherosclerotic CVD Risk and Advanced Lipid Testing

Published:

15 July 2020

Citation:

European Cardiology Review 2020;15:e56.

The Coronary Intravascular Lithotripsy System

Citation:

Interventional Cardiology Review 2019;14(3):174–81.